Healthy Volunteer Clinical Trial
Official title:
Color Vision as an Outcome Measure for Clinical Trials of Inherited Retinal Degenerations
Background:
- The purpose of this study is to find out whether color vision measured with the Cambridge
Color Test is a good way to examine the severity of inherited retinal diseases (IRDs). IRDs
are a major cause of vision loss worldwide, but very little is known about how the diseases
affect color vision over time. This study will tell us if color vision may be used to track
changes in inherited retinal diseases over time.
Objectives:
- To improve understanding of color vision as a way to measure changes in inherited retinal
diseases.
Eligibility:
- People 5 years of age or older who have an IRD.
- Healthy volunteers at least 5 years of age.
Design:
- Participants will make at least one visit to the National Eye Institute clinic. If they
sign up for more tests, they may have up to three visits to the NEI clinic.
- Participants will be asked questions about their medical and eye history.
- Participants will be given an eye exam, including eye drops to dilate their pupils. They
will take the Cambridge Color Test, which includes looking at a monitor and pressing a
button, and arranging colored circles. Several other tests may be offered, but
participants can decline to take them.
- Treatment will not be provided as part of this study.
Objective: The aims of this study are to 1) examine the sensitivity of the Cambridge Color
Test (CCT) and the low vision CCT (LvCCT) to the severity of retinal disease in inherited
retinal degeneration (IRD) by comparing color vision status with changes in photoreceptor
structure and function, 2) examine the effects of eccentric fixation and reduction in visual
acuity on color discrimination thresholds obtained with the CCT and LvCCT, and 3) establish
normal ranges for the CCT and the LvCCT and determine the intra-session and inter-session
variabilities for these tests.
Study Population: Up to 59 healthy volunteers and 144 IRD participants age 5 or older will be
enrolled in this study.
Design: This study will be comprised of three related projects. For Aim 1, color
discrimination thresholds (CCT and LvCCT) and assessments of retinal structure (imaging) and
function (perimetry/microperimetry and electroretinogram) will be measured in 144 IRD
participants with varying retinal phenotypes and visual acuities. IRD participants will be
divided into four major categories: 1) cone & cone-rod dystrophies, 2) rod-cone dystrophies,
3) inherited maculopathies, and 4) inherited retinal dysfunction syndromes. The fourth
category will be used for IRDs that do not match the description for categories 1-3 (i.e.,
x-linked retinoschisis, congenital stationary night blindness). Degree of severity of retinal
dysfunction in IRD participants will be determined relative to the normal ranges obtained
from the healthy volunteers (see Aim 3a below). For Aim 2 color discrimination thresholds
(CCT and LvCCT) will be measured in one eye from 12 healthy volunteers in order to examine
the effects of eccentric fixation and reduced visual acuity on color thresholds independent
of retinal pathology. Between one and three study visits will be required for this aim. Aim 3
will be comprised of two parts. For Aim 3a, color thresholds will be collected from both eyes
(for intraocular variability) of 35 healthy volunteers age 5 or older. For Aim 3B, color
discrimination thresholds (CCT and LvCCT) will measured from 12 healthy volunteers twice in
one session and then again at a second visit occurring within two months of the initial visit
to determine intra-session and inter-session variability.
Outcome Measures: For both the CCT and LvCCT, an overall quantitative measure of color vision
will be obtained from the calculation of achromatic area. The sensitivity of CCT and LvCCT
will be examined by comparing achromatic area for IRD participants with varying levels of
phenotype severity defined by measures of retinal structure and function. Secondary outcomes
for this study include: 1) evaluation of sensitivity of the CCT and LvCCT to disease
severity,
2) evaluation of the effects of decreased visual acuity and eccentricity on color
discrimination thresholds (CCT and LvCCT), 3) establishment of the normal range of color
discrimination thresholds (CCT and LvCCT) as a function of age, and 4) determination of
intra- and inter-session variabilities of the two tests.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06326723 -
Investigate the PK, Safety, and Tolerability After Single and Multiple Dose Daridorexant in Chinese Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT00001367 -
Diagnosis and History Study of Patients With Different Neurological Conditions
|
||
Completed |
NCT02699710 -
Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects
|
Phase 1 | |
Completed |
NCT02231892 -
Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study
|
N/A | |
Not yet recruiting |
NCT06441916 -
Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions
|
Phase 1 | |
Completed |
NCT03771586 -
A Study to Assess the Electrophysiology, Safety, Tolerability, and Pharmacokinetics of SAGE-718 Using a Ketamine Challenge in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06337422 -
Bioequivalence Study of Generic Celecoxib 200 mg Capsules
|
Phase 1 | |
Completed |
NCT03302182 -
Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT05049343 -
Study of SAGE-904 Using a Ketamine Challenge to Evaluate Electrophysiology, Safety, Tolerability, and Pharmacokinetics in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT01629108 -
Normal Values in Hearing and Balance Testing
|
||
Completed |
NCT02947854 -
Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant
|
Phase 1 | |
Completed |
NCT02534870 -
Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT02224053 -
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01676584 -
A Study of Single Dose RO6811135 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01697436 -
A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets
|
Phase 1 | |
Completed |
NCT01711762 -
A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01684891 -
A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers
|
Phase 1 | |
Completed |
NCT01591850 -
A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01461967 -
A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01433575 -
A Pharmacokinetic Study of RO4917838 in Healthy Chinese Volunteers
|
Phase 1 |